Consistency of Response With Rimegepant in Acute Treatment of Migraine

Sponsor
Pfizer
Study ID
NCT06898047
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This is a non-interventional, prospective study that will enroll participants with migraine in the United Kingdom currently in use of rimegepant to acutely treat migraine attacks. Participants will be followed up for up to 12 weeks and will complete a daily questionnaire to self-report the consistency of response to rimegepant in acute treatment of migraine.

Key Dates

Start date
Nov 15, 2025
Status verified
May 2026
Primary completion
Jul 31, 2026
Completion
Jul 31, 2026

Study Design

Enrollment
250 participants (estimated)

Arms

  • Arm: Rimegepant users
    Participants with current prescription of rimegepant for acute treatment of migraine
  • Arm: Rimegepant-treated attacks
    Migraine attacks treated with rimegepant

Primary Outcome Measure

Time to Meaninful Pain Relief (MPR) post-dosing [ Time Frame: Daily (within 24hs post dose) ]

Related Studies